Long-acting pre-exposure prophylaxis (PrEP) options are being evaluated to expand HIV prevention choices. Monthly oral PrEP such as MK-8527 may offer a low-cost, self-administered option suitable for community-based delivery, while injectable lenacapavir provides longer protection per administration. The study adapted an agent-based network model to estimate the health and economic impact of scaling up MK-8527 alone, lenacapavir alone, and combined strategies in western Kenya and South Africa, comparing each to a baseline of daily oral PrEP.
The authors used the EMOD-HIV agent-based network model to simulate PrEP scale-up from 2026 through 2035 in two settings: South Africa and western Kenya. Scenarios varied uptake levels across priority groups, including female sex workers (FSWs), their male clients, and people with more than one sexual partner. Results were reported as infections averted, disability-adjusted life years (DALYs) averted, costs, and incremental cost-effectiveness ratios (ICERs) compared to the baseline of daily oral PrEP only.
Three primary intervention strategies were modeled: MK-8527 alone, lenacapavir alone, and combined MK-8527 + lenacapavir. The model assumed identical uptake rates across strategies for comparison. Cost assumptions included pill prices for MK-8527 at US$1.00 and US$2.50 per pill; provision cost comparisons with lenacapavir were based on these assumptions. The analytic perspective and discounting assumptions were not detailed in the source summary.
Effectiveness inputs used in the model were 95% effectiveness for MK-8527 for a 2-month protection window (on the basis that individuals took two of three pills dispensed) and 95% effectiveness for lenacapavir for 6 months. Uptake parameters varied by population subgroups, but precise numerical uptake rates for each subgroup were not reported in the source summary.
When modeled with the same uptake levels, MK-8527 averted fewer HIV infections than lenacapavir in both settings. Reported ranges for infections averted were 6–14% for MK-8527 alone versus 11–18% for lenacapavir alone. Combined strategies of MK-8527 plus lenacapavir increased the proportion of infections averted further, with combined scenarios producing 13–23% infections averted.
Provision costs for MK-8527 were substantially lower than for lenacapavir under the price assumptions used. At a pill price of US$1.00, MK-8527 provision costs were 58–59% lower than lenacapavir; at US$2.50 per pill, provision costs were 40–43% lower. In western Kenya, MK-8527 alone produced ICERs of US$467 per DALY averted at US$1.00 per pill and US$799 per DALY averted at US$2.50 per pill. For lenacapavir in western Kenya the ICER was US$1,306 per DALY averted. In South Africa, all long-acting PrEP strategies were reported as cost-saving over a 35-year horizon.
Service delivery represented the majority of MK-8527 program costs: approximately 73% of total costs when pill price was US$1.00. This indicates that non-drug components—clinic visits, staffing, outreach, and other delivery expenses—were dominant drivers of program cost under the modeled scenarios.
Combining MK-8527 and lenacapavir increased overall health benefits relative to either product alone, with modeled infections averted of 13–23%. However, combined strategies incurred higher provision costs than single-product strategies, reflecting additive service delivery and product costs.
Although modeled long-acting PrEP strategies were cost-saving over a 35-year horizon in South Africa, near-term budget impacts were substantial. The authors reported five-year budget impacts in the range of US$169–348 million, indicating that upfront financing needs could be a barrier despite favorable long-run cost-effectiveness.
Under the model assumptions, MK-8527 can reduce HIV incidence at lower provision cost than injectable lenacapavir and may be cost-effective or cost-saving depending on setting, pill price, and targeting. Key determinants of MK-8527’s economic attractiveness included low pill prices (for example, US$1.00 per pill in the scenarios) and focused provision to populations at substantial HIV risk. High service delivery costs limit cost-effectiveness unless commodity prices are low and programs are efficiently targeted.
The source summary did not provide some methodological details such as exact uptake rates by subgroup, discounting and analytic perspective, or full breakdown of service delivery components. Those details were not reported in the provided source text and would need to be consulted in the full preprint for complete economic-methods transparency.
Policymakers and program planners should weigh near-term budget impacts against long-term cost-savings, consider strategies to reduce service delivery costs, and prioritize targeting to high-risk groups to maximize the health and economic returns of introducing monthly oral MK-8527 alongside or instead of injectable lenacapavir. Further operational and pricing data will be important for implementation decisions.